O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
(+6.3%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-4.53%
Top 10 Holdings %
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18
Avg Time Held Equity + Options
2.2
years
Top 10 Avg Time Held Equity + Options
1.9
years
Top 20 Avg Time Held Equity + Options
1.8
years
Avg Time Held Equity only
2.4
years
Top 10 Avg Time Held Equity only
1.9
years
Top 20 Avg Time Held Equity only
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Danaher
DHR
|
+$52.4M |
| 2 |
Cigna
CI
|
+$48.2M |
| 3 |
United Therapeutics
UTHR
|
+$38.6M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$29.4M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$28.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$105M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$93.6M |
| 3 |
Tenet Healthcare
THC
|
+$81.8M |
| 4 |
Boston Scientific
BSX
|
+$39.8M |
| 5 |
Cytokinetics
CYTK
|
+$35.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.63% |
| 2 | Miscellaneous | 2.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Corvus Pharmaceuticals
CRVS
$781M
| $52.8M | 1.24% |
7,165,006
| – | – |
2016 Q1
38 quarters
|
|
27
DELISTED
Apellis Pharmaceuticals
APLS
| $52.6M | 1.24% |
2,323,368
+841,068
| +57% | +$19.6M |
2025 Q1
2 quarters
|
|
|
28
Danaher
DHR
$158B
| $52.2M | 1.23% |
+263,100
| New | +$52.4M |
2025 Q3
0 quarters
|
|
29
Neurocrine Biosciences
NBIX
$13.8B
| $49.6M | 1.17% |
353,640
-84,900
| -19% | -$11.5M |
2018 Q1
30 quarters
|
|
|
30
United Therapeutics
UTHR
$23.4B
| $48.2M | 1.13% |
+114,900
| New | +$38.6M |
2025 Q3
0 quarters
|
|
|
31
Cigna
CI
$76.3B
| $46.9M | 1.1% |
+162,800
| New | +$48.2M |
2025 Q3
0 quarters
|
|
32
DELISTED
Crinetics Pharmaceuticals
CRNX
| $45.8M | 1.08% |
1,099,000
-50,000
| -4% | -$1.6M |
2018 Q3
28 quarters
|
|
|
33
Oric Pharmaceuticals
ORIC
$1.2B
| $43.7M | 1.03% |
3,641,756
+2,742,475
| +305% | +$28.9M |
2025 Q1
2 quarters
|
|
34
Janux Therapeutics
JANX
$1.05B
| $43.2M | 1.01% |
1,766,100
+555,800
| +46% | +$13.5M |
2021 Q2
17 quarters
|
|
35
Roivant Sciences
ROIV
$24.3B
| $41.1M | 0.97% |
2,714,798
-64,629
| -2% | -$800K |
2025 Q2
1 quarter
|
|
|
36
Ascendis Pharma A/S
ASND
$14.9B
| $38.2M | 0.9% |
191,905
+157,505
| +458% | +$29.4M |
2025 Q2
1 quarter
|
|
37
SI-BONE Inc
SIBN
$878M
| $38M | 0.89% |
2,578,979
| – | – |
2020 Q1
22 quarters
|
|
38
DELISTED
scPharmaceuticals
SCPH
| $34.4M | 0.81% |
6,059,528
| – | – |
2017 Q4
31 quarters
|
|
39
Abivax
ABVX
$7.65B
| $32.3M | 0.76% |
+380,000
| New | +$23.3M |
2025 Q3
0 quarters
|
|
40
Structure Therapeutics
GPCR
$1.56B
| $31.9M | 0.75% |
1,139,300
-60,000
| -5% | -$1.2M |
2024 Q2
5 quarters
|
|
41
Trevi Therapeutics
TRVI
$1.75B
| $30.3M | 0.71% |
3,308,400
| – | – |
2025 Q1
2 quarters
|
|
42
Integer Holdings
ITGR
$4.31B
| $30M | 0.7% |
290,000
-143,400
| -33% | -$15.6M |
2024 Q2
5 quarters
|
|
43
Dyne Therapeutics
DYN
$2.79B
| $29.3M | 0.69% |
2,314,184
+1,282,784
| +124% | +$14.6M |
2024 Q1
6 quarters
|
|
44
DELISTED
RAPT Therapeutics
RAPT
| $28M | 0.66% |
1,086,618
-555,288
| -34% | -$7.27M |
2024 Q4
3 quarters
|
|
45
CytomX Therapeutics
CTMX
$482M
| $27M | 0.63% |
8,461,500
| – | – |
2025 Q2
1 quarter
|
|
46
Neuropace
NPCE
$431M
| $27M | 0.63% |
2,614,184
| – | – |
2021 Q2
17 quarters
|
|
47
uniQure
QURE
$1.42B
| $26.8M | 0.63% |
+458,500
| New | +$8.32M |
2025 Q3
0 quarters
|
|
48
EyePoint Inc
EYPT
$260M
| $25.6M | 0.6% |
+1,796,000
| New | +$20.7M |
2025 Q3
0 quarters
|
|
49
DELISTED
Akero Therapeutics
AKRO
| $25M | 0.59% |
526,200
+314,900
| +149% | +$15.2M |
2024 Q4
3 quarters
|
|
50
ADC Therapeutics
ADCT
$188M
| $23.6M | 0.56% |
5,907,351
| – | – |
2024 Q2
5 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q3 2025 Portfolio in Review
As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.
- OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
- OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
- OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
- OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
- OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
- OrbiMed opened 24 new positions and closed 18 in Q3 2025.
- OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.
Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.